Focused Wealth Management’s Aoxing Pharmaceutical Company Inc. AXN Stock Holding History

Focused Wealth Management’s Portfolio AXN Stock Details AXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-7,435	Closed	-$2K	–	762
2017 Q2	$2K	Hold	7,435	–	–	﹤0.01%	652
2017 Q1	$3K	Hold	7,435	–	–	﹤0.01%	606
2016 Q4	$2K	Hold	7,435	–	–	﹤0.01%	632
2016 Q3	$4K	Sell	7,435 -13,715	-65%	-$9.22K	﹤0.01%	563
2016 Q2	$14K	Buy	+21,150	New	+$14.3K	0.01%	406

Other funds holding AXN

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Focused Wealth Management's AXN Position: Q3 2017 in Review

Focused Wealth Management sold out of Aoxing Pharmaceutical Company Inc. (AXN) in Q3 2017, closing a stake of 7,435 shares — an estimated $2K sold.

Focused Wealth Management first reported a position in AXN in Q2 2016 and held it in 5 quarters. The position peaked at $14K in Q2 2016. 8 funds tracked by Wall St. Rank hold AXN as of Q3 2017.

Focused Wealth Management reported no remaining Aoxing Pharmaceutical Company Inc. position as of Q3 2017 after selling out during the quarter.
Focused Wealth Management sold 7,435 Aoxing Pharmaceutical Company Inc. shares in Q3 2017, an estimated $2K.
Focused Wealth Management first reported a position in Aoxing Pharmaceutical Company Inc. in Q2 2016 and held it in 5 quarters.
Focused Wealth Management's Aoxing Pharmaceutical Company Inc. position peaked at $14K in Q2 2016.
8 funds tracked by Wall St. Rank held Aoxing Pharmaceutical Company Inc. as of Q3 2017.

Based on Focused Wealth Management's 13F filing for Q3 2017, filed 14 Nov 2017.